DOV 216,303, a "triple" reuptake inhibitor: Safety, tolerability, and pharmacokinetic profile

Journal of Clinical Pharmacology

Volumn 44, Issue 12, 2004, Pages 1360-1367

  Beer, Bernard ^a   Stark, Jill ^a   Krieter, Philip ^a   Czobor, Pal ^a   Beer, Gary ^a   Lippa, Arnold ^a   Skolnick, Phil ^a  

^a DOV Pharmaceutical Inc   (United States)

Author keywords

Antidepressives; DOV 216,303; Drug safety; Pharmacokinetics; Triple reuptake inhibitors

Indexed keywords

1 (3,4 DICHLOROPHENYL) 3 AZABICYCLO[3.1.0]HEXANE; BIOGENIC AMINE; DOV 216303; PLACEBO; SEROTONIN UPTAKE INHIBITOR; UNCLASSIFIED DRUG;

ANALYTIC METHOD; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DRUG ABSORPTION; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; GASTROINTESTINAL SYMPTOM; HEMORRHOID; HUMAN; METEORISM; NAUSEA; SIDE EFFECT;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ANTIDEPRESSIVE AGENTS; AREA UNDER CURVE; AZA COMPOUNDS; BICYCLO COMPOUNDS, HETEROCYCLIC; CAPSULES; DIGESTIVE SYSTEM; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; HALF-LIFE; HUMANS; MALE; MOLECULAR STRUCTURE; NEUROTRANSMITTER UPTAKE INHIBITORS;

EID: 8744220539     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/0091270004269560     Document Type: Article

References (21)

1. Skolnick P, ed. Antidepressants: New Pharmacological Strategies. Totowa, NJ: Humana Press; 1997.
2. Kent JM. SNaRIs, NASSAs, and NaRIs: new agents for the treatment of depression. Lancet. 2000;355:911-918.
3. Paul IA. Excitatory amino acid signalling, major depression and the actions of antidepressants. Pharmaceut News. 2001;8:33-44.
4. Rupniak NM, Kramer MS. Discovery of the antidepressant and anti-emetic efficacy of substance P receptor (NK1) antagonists. Trends Pharmacol Sci. 1999;20:485-490.
5. Skolnick P, Legutko B, Li X, Bymaster FP: Current perspectives on the development of non-biogenic amine based antidepressants. Pharmacological Res. 2001;43:411-423.
6. Nowak G, Szewczyk B. Mechanisms contributing to antidepressant zinc actions. Pol J Pharmacol. 2002;54:587-592.
7. Romero L, Casanovas JM, Hervas I, Cortes R, Artigas F. Strategies to optimize the antidepressant action of selective serotonin reuptake inhibitors. In: Skolnick P, ed. Antidepressants: New Pharmacological Strategies. Totowa, NJ: Humana Press; 1997:1-33.
8. Skolnick P. Antidepressants beyond monoamine-based therapies: clues to new approaches. J Clin Psychiatry. 2002;63:19-23.
9. D'Aquila PS, Collu M, Gessa GL, Serra G. The role of dopamine in the mechanism of action of antidepressant drugs. Eur J Pharmacol. 2000;405:365-373.
10. Brunello N, Mendlewicz J, Kasper S, et al. The role of noradrenaline and selective noradrenaline reuptake inhibition in depression. Eur Neuropsychopharm. 2002;12:461-475.
11. Willner P. Dopaminergic mechanisms in depression and mania. In: Watson S, ed. Psychopharmacology: The Fourth Generation of Progress. New York: Lippincott Williams & Wilkins; 2000.
12. Skolnick P, Popik P, Janowsky A, Beer B, Lippa A. "Broad spectrum" antidepressants: is more better for the treatment of depression? Life Sci. 2003;73:3175-3179.
13. Eshleman AJ, Carmolli M, Cumbay M, et al. Characteristics of drug interactions with recombinant biogenic amine transporters expressed in the same cell type. J Pharmacol Exp Ther. 1999;289:877-885.
14. Porsolt RD, Bertin A, Jalfre M. Behavioral despair in mice: a primary screening test for antidepressants. Arch Int Pharmacodyn Ther. 1977;229:327-336.
15. Borsini F, Meli A. Is the forced swim test a suitable model for revealing antidepressant activity? Psychopharmacology. 1988;94:147-160.
16. Cryan JF, Markou A, Lucki I. Assessing antidepressant activity in rodents: recent developments and future needs. Trends Pharmacol Sci. 2002;23:238-245.
17. Detke MJ, Lu Y, Goldstein DJ, Hayes JR, Demitrack MA. Duloxetine, 60 mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trial. J Clin Psychiatry. 2002;63:308-315.
18. Chalon SA, Grainer L-A, Vandenhende FR, et al. Duloxetine increases serotonin and norepinephrine availability in healthy subjects: a double-blind, controlled study. Neuropsychopharmacology. 2003;28:1685-1693.
19. Chalon S, Bieck PR, Goldstein DJ, Bymaster FP, Potter WZ, Demitrack MA. The tyramine pressor test may have limited sensitivity, especially in the presence of dual serotonin/norepinephrine uptake inhibition. Neuropsychopharmacology. 2002;26:698-699.
20. Haryey AT, Rudolph RL, Preskorn SH. Evidence of the dual mechanisms of action of venlafaxine. Arch Gen Psychiatry. 2000;57:503-509.
21. Yyldyz A, Sachs GS. Administration of antidepressants: single versus split dosing: a meta-analysis. J Affect Dis. 2001;66:199-206.